Drugs / [18F]-JNJ-70099731
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04911543 | Jun 2021 → Feb 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]-JNJ-70099731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04911543 ↗ |
| Modality | Diagnostic / imaging agent | “Positron Emission Tomography Ligand” NCT04911543 ↗ |
| Route | Intravenous | “\[18F\]JNJ-70099731 injection will be administered intravenously.” NCT04911543 ↗ |